$5.33 4%
INO Stock Price vs. AI Score
Data gathered: October 7

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Inovio Pharmaceuticals

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.


Inovio Pharmaceuticals
Price $5.33
Target Price Sign up
Volume 364,450
Market Cap $144M
Year Range $4.9 - $13.88
Dividend Yield 0%
Analyst Rating 50% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q2 '241.4M10M-8.8M-32M0-1.190
Q1 '24630,00011M-9.9M-30M-31M-1.310
Q4 '23730,00010M-9.5M-25M-27M-1.120
Q3 '232M20M-18M-34M-36M-0.130
Q2 '232.1M14M-11M-36M-37M-0.130

Insider Transactions View All

Zoth Lota S. filed to sell 52,716 shares at $0.6.
June 5 '23
Weiner David B. filed to sell 910,124 shares at $1.2.
March 13 '23
Weiner David B. filed to sell 904,291 shares at $1.3.
February 28 '23
Weiner David B. filed to sell 892,625 shares at $2.7.
August 11 '22
BENITO SIMON X filed to sell 75,305 shares at $2.3.
July 20 '22

What is the Market Cap of Inovio Pharmaceuticals?

The Market Cap of Inovio Pharmaceuticals is $144M.

What is the current stock price of Inovio Pharmaceuticals?

Currently, the price of one share of Inovio Pharmaceuticals stock is $5.33.

How can I analyze the INO stock price chart for investment decisions?

The INO stock price chart above provides a comprehensive visual representation of Inovio Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Inovio Pharmaceuticals shares. Our platform offers an up-to-date INO stock price chart, along with technical data analysis and alternative data insights.

Does INO offer dividends to its shareholders?

As of our latest update, Inovio Pharmaceuticals (INO) does not offer dividends to its shareholders. Investors interested in Inovio Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Inovio Pharmaceuticals?

Some of the similar stocks of Inovio Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.